Mirtazapine in Alzheimer-associated Weight Loss
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01505504|
Recruitment Status : Completed
First Posted : January 6, 2012
Last Update Posted : January 6, 2012
Weight loss is a frequent problem associated with Alzheimers disease (AD). Mirtazapine has weight loss as a frequent side effect.
The aim of this retrospective study is to check whether mirtazapine 30 mg (once daily) can counteract weight loss in patients with AD or mixed dementia (AD + vascular).
|Condition or disease||Intervention/treatment|
|Alzheimer's Disease Weight Loss Mixed Dementia Dementia||Drug: mirtazapine|
|Study Type :||Observational|
|Actual Enrollment :||22 participants|
|Official Title:||Mirtazapine in Alzheimer-associated Weight Loss: a Retrospective Phase IV Study|
|Study Start Date :||January 2004|
|Actual Primary Completion Date :||November 2011|
|Actual Study Completion Date :||December 2011|
- Drug: mirtazapine
30 mg at bedtimeOther Name: Remergon
- body weight [ Time Frame: 6 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01505504
|Brussels, Belgium, 1020|